# MingCeler

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mingceler

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.mingceler.com
- Latest round: Series A (Jul 13, 2026)
- Investors on record: 2

## About

Based in Guangzhou, China and founded in 2022, Guangzhou MingCeler Biotechnology Co., Ltd., trading as MingCeler, is a biotechnology company focusing on genetically engineered animal model development and next-generation laboratory animal technologies. The company is a joint incubator of Guangzhou Laboratory and Bio Island Laboratory. Its founder Guangming Wu is a researcher at Guangzhou National Laboratory and his name is on permanent display at the Deutsches Museum, Germany. The company has established AAALAC international certification and ISO quality management systems, setting industry benchmarks in product quality, research ethics, and social responsibility. In July 2026, it closed a series A funding round. MingCeler specializes in the development of genetically engineered animal models and related research services for biomedical, pharmaceutical, and life sciences applications. The company's core offering is the rapid customization of gene-edited mouse models using its proprietary TurboMice™ tetraploid complementation technology, which enables researchers to obtain homozygous genetically modified mice in significantly shorter timeframes compared to traditional breeding approaches. The company generates revenue primarily through the development and commercialization of genetically engineered animal models for biomedical research and preclinical drug development. The company will use the series A funding to expand the capacity of the SPF laboratory animal facility, establish a unique precision gene-edited embryonic stem cell seed bank based on the TurboMice™ platform to meet the needs of domestic and international industrial clients, and build an overseas sales team.

## Funding rounds

- Series A, Jul 13, 2026 — Syn Capital, Haikou Gangyin

## Investors

- Syn Capital — Series A
- Haikou Gangyin — Series A